Literature DB >> 11966681

CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.

Joyce A Goldstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11966681      PMCID： PMC1874266          DOI： 10.1046/j.1365-2125.2002.01572_7.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.

Authors:  L J Dickmann; A E Rettie; M B Kneller; R B Kim; A J Wood; C M Stein; G R Wilkinson; U I Schwarz
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

2.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

3.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

Authors:  R S Kidd; T B Curry; S Gallagher; T Edeki; J Blaisdell; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-12

4.  Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.

Authors:  I Ieiri; K Mamiya; A Urae; Y Wada; M Kimura; S Irie; T Amamoto; T Kubota; S Yoshioka; K Nakamura; S Nakano; N Tashiro; S Higuchi
Journal:  Br J Clin Pharmacol       Date:  1997-04       Impact factor: 4.335

5.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.

Authors:  C L Crespi; V P Miller
Journal:  Pharmacogenetics       Date:  1997-06

6.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

Authors:  U Yasar; E Eliasson; M L Dahl; I Johansson; M Ingelman-Sundberg; F Sjöqvist
Journal:  Biochem Biophys Res Commun       Date:  1999-01-27       Impact factor: 3.575

7.  Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

Authors:  S L Wang; J Huang; M D Lai; J J Tsai
Journal:  Pharmacogenetics       Date:  1995-02
  7 in total
  1 in total

1.  Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.

Authors:  Rosangela Invernizzi; Federica Quaglia; Catherine Klersy; Fabio Pagella; Federica Ornati; Francesco Chu; Elina Matti; Giuseppe Spinozzi; Sara Plumitallo; Pierangela Grignani; Carla Olivieri; Raffaella Bastia; Francesca Bellistri; Cesare Danesino; Marco Benazzo; Carlo L Balduini
Journal:  Lancet Haematol       Date:  2015-10-27       Impact factor: 18.959
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.